AIM ImmunoTech (NYSE:AIM) Trading Down 5.7% – Here’s Why

Posted by Maddie Sorensen on Jan 2nd, 2025

AIM ImmunoTech Inc. (NYSE:AIM – Get Free Report)’s share price fell 5.7% during trading on Tuesday . The stock traded as low as $0.19 and last traded at $0.20. 915,238 shares changed hands during trading, an increase of 198% from the average session volume of 307,402 shares. The stock had previously closed at $0.21.

Wall Street Analysts Forecast Growth

AIM has been the topic of a number of research analyst reports. Ascendiant Capital Markets lowered their price objective on shares of AIM ImmunoTech from $5.00 to $4.50 and set a “buy” rating on the stock in a research note on Tuesday, December 10th. Maxim Group decreased their target price on AIM ImmunoTech from $2.00 to $1.00 and set a “buy” rating for the company in a research note on Tuesday, October 22nd.

Get Our Latest Stock Report on AIM

AIM ImmunoTech Price Performance

The business has a 50-day moving average price of $0.22 and a 200 day moving average price of $0.29. The company has a market cap of $13.66 million, a price-to-earnings ratio of -0.46 and a beta of -0.36. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 0.05.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in AIM ImmunoTech stock. Armistice Capital LLC purchased a new stake in shares of AIM ImmunoTech Inc. (NYSE:AIM – Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 4,078,000 shares of the company’s stock, valued at approximately $1,520,000. Armistice Capital LLC owned approximately 7.92% of AIM ImmunoTech as of its most recent SEC filing. Hedge funds and other institutional investors own 12.02% of the company’s stock.

AIM ImmunoTech Company Profile

(Get Free Report)

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).